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Abstract The human uncoupling protein 3 gene generates two 
mRNA transcripts, uncoupling protein 3L and uncoupling 
protein 3S, which are predicted to encode long and short forms 
of the uncoupling protein 3 protein, respectively. While 
uncoupling protein 3L is similar in length to the other known 
uncoupling proteins, uncoupling protein 3S lacks the last 37 C- 
terminal residues. A splice site mutation in the human uncoupling 
protein 3 gene, resulting in the exclusive xpression of uncoupling 
protein 3S, and a number of point mutations in the uncoupling 
protein 3 gene have been described. This study compares the 
biochemical activity of uncoupling protein 3S as well as three 
mutants of the uncoupling protein 3 gene (V9M, V102I, R282C) 
with that of uncoupling protein 3L utilizing a yeast expression 
system. All proteins were expressed at similar levels and had 
qualitatively similar effects on parameters related to the 
uncoupling function. Both uncoupling protein 3S and uncoupling 
protein 3L decreased the yeast growth rate by 35 and 52%, 
increased the whole yeast basal Oz consumption by 26 and 48%, 
respectively, and decreased the mitochondrial membrane poten- 
tial as measured in whole yeast by uptake of the fluorescent 
potential-sensitive dye 3'3-dihexyloxacarbocyanine iodide. In 
isolated mitochondria, uncoupling protein 3S and uncoupling 
protein 3L caused a similar (33 and 35%, respectively) increase 
in state 4 respiration, which was relatively small compared to 
uncoupling protein 1 (102% increase). A truncated version of 
uncoupling protein 3S, lacking the last three C-terminal residues, 
Tyr, Lys and Gly, that are part of a carrier motif that is highly 
conserved among all mitochondrial carriers, had a greatly 
reduced uncoupling activity. The two naturally occurring 
uncoupling protein 3 mutants, V9M and V102I, were similar to 
uncoupling protein 3L with respect o effects on the yeast growth 
and whole yeast Oz consumption. The R282C mutant had a 
reduced effect compared to uncoupling protein 3L. In summary, 
uncoupling protein 3S and the three mutants of uncoupling 
protein 3 appear to be functional proteins with biochemical 
activities similar to uncoupling protein 3L, although uncoupling 
protein 3S and the R282C mutant have a modestly reduced 
function. 
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1. Introduction 
Uncoupling proteins (UCPs) are members of the mitochon- 
drial carrier family. Based on a high homology and available 
functional data, UCPs are believed to represent a subfamily 
among the larger mitochondrial carrier superfamily. UCP1 
was the first UCP to be identified [1 5] and biochemically 
characterized. UCP1 uncouples mitochondrial respiration 
from ATP synthesis by decreasing the transmembrane proton 
gradient [6-8]. The activity of UCP1 is inhibited by purine 
nucleotides, uch as GDP [6]. UCP1 is expressed exclusively 
in brown adipose tissue where it is believed to play an impor- 
tant role in thermogenesis. 
Recently, a number of proteins with high homology to 
UCP1 were identified, including UCP2 [9,10], which is widely 
expressed, and UCP3 [11-13], which is expressed primarily in 
skeletal muscle. Functional studies of the various UCPs, using 
yeast or mammalian cell expression systems, have been pub- 
lished [9,10,13-16], indicating that UCP2 and UCP3 both 
have uncoupling activity. In a recent study of UCP3 using a 
yeast expression system, we found that the uncoupling activity 
of UCP3 differs from UCP1 [17]. In whole yeast, UCP3 was 
found to reduce yeast growth and increase the whole yeast 
basal 02 consumption to a greater extent than UCP1. In 
contrast o the strong effects of UCP3 in whole yeast, the 
increase in state 4 respiration in isolated mitochondria of 
yeast bearing UCP3 was small compared to that observed 
with UCP1. This discordance between the stronger effect of 
UCP3 in whole yeast and the weak effect in isolated mito- 
chondria compared to UCP1, as well as the finding that 
UCP3 in contrast o UCP1 is not subject o tight GDP in- 
hibition, suggests a different regulation of the two UCPs. 
The human UCP3 gene generates two mRNA transcripts, 
UCP3L, encoding a protein similar in length to UCP1 and 
UCP2, and UCP3S, encoding a protein which lacks the last 37 
C-terminal residues [11,18]. These 37 residues are encoded by 
exon 7 which is missing from UCP3S due to a cleavage and 
polyadenylation signal in intron 6. Termination of message 
elongation at this polyadenylation signal occurs approxi- 
mately 50% of the time. If the polyadenylation signal in intron 
0014-5793/99/$20.00 © 1999 Federation of European Biochemical Societies. All rights reserved. 
PII: S0014-5793(99)0081 1-X 
202 
6 is bypassed, message elongation proceeds until a second 
polyadenylation signal, located downstream of exon 7, is 
reached and thus, UCP3L is generated [18]. Mice do not ex- 
press a transcript which is equivalent o human UCP3S [19]. 
In mouse, a UCP3 variant mRNA,  murine UCP3S, was found 
[19]. The predicted protein lacks the last 94 C-terminal resi- 
dues. Murine UCP3S mRNA was much less abundant  han 
murine UCP3L. 
All known members of the mitochondrial  carrier superfam- 
ily are believed to have six t ransmembrane domains [20,21]. In 
contrast to UCP3L, UCP1 and UCP2, the putative human 
UCP3S lacks the sixth C-terminal t ransmembrane domain. 
Thus, it is possible that UCP3S is unstable and/or inactive. 
Import of UCP3S into the inner mitochondrial  membrane or 
the function of UCP3S may be impaired. 
In a recent study by Argyropoulos et al. [22], a heterozy- 
gous polymorphism in the splice donor junct ion of exon 6 was 
found in 20% of Gul lah-speaking African Americans and 16% 
of members of the Mende tribe in Sierra Leone, but not in 
Caucasians. No homozygous ubjects for the polymorphism 
were detected among the Gullah-speaking African Americans. 
1% homozygotes among the members of the Mende tribe. 
This polymorphism results in loss of the splice function and 
is therefore predicted to give rise to a protein that is identical 
to UCP3S. Argyropoulos et al. [22] also showed reduced basal 
fat oxidation rates and increased respiratory quotients in the 
group of heterozygotes for the polymorphism, suggesting that 
UCP3S has a reduced or no function. 
A different study by Chung et al. [23] identified heterozy- 
gous as well as homozygous individuals for the splice site 
mutation, predicted to give rise to the UCP3S protein, among 
an African American population. In addition, three DNA 
sequence variants in the UCP3 gene were found which result 
in the alteration of three amino acids (V9M, V102I, R282C) 
that are highly conserved among the UCPs. No consistent and 
significant metabolic phenotype was associated with the splice 
site mutat ion or any of the three point mutat ions except for a 
small elevation of the plasma glucose concentrat ion i  indi- 
viduals with the V9M mutation. 
A study by Millet et al. [24] found no difference in the 
absolute amount  and ratio of UCP3L and UCP3S mRNA 
in lean versus obese subjects, indicating that obesity in these 
patients is not caused by altered transcription or alternative 
splicing of the UCP3 gene. Caloric restriction resulted in a 
3-fold parallel increase in both UCP3L and UCP3S mRNA,  
which suggests that there is no regulation of UCP3 gene ex- 
pression at the level of alternative splicing. 
In this study, we utilized a yeast heterologous expression 
system to compare the biochemical activity of the long and 
short form of UCP3 and the three UCP3 sequence variants. 
We have previously used the yeast growth rate, whole yeast 
O2 consumption and state 4 respiration in isolated mitochon- 
dria to assess the biochemical activity of UCP3L in compar- 
ison to UCP1 and demonstrated uncoupling activity for both 
proteins that appears to be regulated ifferently [17]. Expres- 
sion of the oxoglutarate carrier, a closely related mitochon- 
drial carrier that is thought to have no uncoupling activity, 
had no effect on any of these parameters [17]. Therefore, the 
yeast expression system appears to be a suitable way of as- 
sessing the activity of UCP3S compared to UCP3L. In this 
study, a truncated UCP3S, lacking the last three C-terminal 
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residues (Tyr, Lys, Gly), that are part of a mitochondrial  
carrier moti f  that is highly conserved among all mitochondrial  
carriers of known sequence [20,21], was studied as an addi- 
tional negative control. 
2. Materials and methods 
2.1. Expression vectors and mutagenesis 
Constructs of human UCP3L and UCP3S using the pYES2 expres- 
sion vector (Invitrogen, Carlsbad, CA, USA) were prepared as pre- 
viously described [17]. The PCR primers used were designed to intro- 
duce HindIII and XbaI sites close to the start and stop codons, 
respectively. To generate mutant UCP3S (mUCP3S), lacking the 
last three C-terminal amino acids of UCP3S, tyrosine, lysine and 
glycine, the codon for tyrosine (TAC) was converted into a stop 
codon (TAA). The three point mutations in the UCP3 gene were 
generated using site-directed mutagenesis (Quickchange site-directed 
mutagenesis kit, Stratagene, La Jolla, CA, USA). The codon for V9 
(GTG) was changed to ATG (codon for methionine), the codon for 
V102 (GTC) to ATC (codon for isoleucine) and the codon for R282 
(CGT) to TGT (codon for cysteine). All sequences were verified by 
DNA sequencing. Carrier gene expression is under the control of the 
gallO-c3"cl promoter. 
The Sacehwwnyees cerevMae strain INVSCI (Invitrogen) was 
transformed with the pYES2 vectors containing these constructs. 
Empty pYES2 vector was transformed as a negative control. 
2.2. Expression q[" the UCPs 
Yeast transformants were selected onto SC-ura plates. Single colo- 
nies were inoculated into a pre-culture grown in SC-ura medium to an 
optical density at 600 nm (OD600) of approximately three. The yeasts 
were diluted to a final OD600 of 0.04 in 500 ml SC-ura medium with 
3% lactate and no glucose and grown at 30°C with vigorous shaking 
to ensure good oxygenation. After approximately 36 h, 1% galactose 
was added and the cells were harvested after 8 12 h. 
2.3. Analysis of expression qf UCP3L, UCP3S and mUCP3S by 
Western blotting 
The expression of the UCPs was detected by Western blotting with 
antibody to human UCP3, that was prepared against a peptide rep- 
resenting residues 147 166 in exon 4, as described in [17]. 
2.4. Measurement of the mitochondrial membrane potential in yeast 
cells 
The mitochondrial membrane potential was measured with the po- 
tential-sensitive dye 3'3-dihexyloxacarbocyanine iodide (DiOC6) (Mo- 
lecular Probes, Eugene, OR, USA) as previously described [17]. 
2.5. Whole yeast 02 consumption 
02 consumption of whole yeast was measured as previously de- 
scribed [17]. Briefly, the basal 02 consumption and maximum 02 
consumption i duced with 2 btM carbonyl cyanide p-(trifluoromethox- 
y)phenylhydrazone (FCCP) were measured in a Clarke type oxygen 
electrode chamber at 25°C with 1 ml cell suspension at a final con- 
centration of 2.5 × l0 s cells/ml in 3% lactate SC medium. 
2.6. Zs'olation q[ yeast mitochondria nd polarography 
Mitochondria were prepared as previously described [17]. Sphero- 
plasts were prepared by enzymatic digestion with zymolyase and mi- 
tochondria were isolated by differential centrifugation alter homoge- 
nization of the spheroplasts. The buffer for mitochondrial isolation 
contained 0.1% bovine serum albumin that was omitted during the 
last washing step. Mitochondrial respiration was measured in a Clarke 
type oxygen electrode at 30°C under the following standard incuba- 
tion conditions. 0.6 M mannitol, 10 mM Tris-maleate pH 6.8, 5 mM 
KHePO4/K2HPO4, 0.5 mM EDTA, 3 mM NADH, 2.5 gg/ml oligo- 
mycin and approximately 0.25 mg mitochondrial protein/ml. 
2. Z Statistical analysis 
Statistical analysis was performed using StatView 4.0 (Abacus Con- 
cept, Berkeley, CA, USA). All results are presented as the mean+ 
S.E.M. The Student's t test was used to evaluate the statistical sig- 
nificance of differences, as indicated in the figure and table legends. 
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Fig. 1. lmmunoblot analysis of the expression f UCP3L, UCP3S 
and mUCP3S in whole yeast and isolated mitochondria. 40 gg pro- 
tein was used for analysis in each lane. 
3. Results 
3.1. Expression of UCP3S and UCP3L 
Expression of UCP3S and UCP3L was confirmed by West- 
ern blot analysis of whole yeast protein and isolated mito- 
chondria obtained 8 h after induction with 1% galactose 
(Fig. 1). Equal amounts of protein were loaded in all lanes. 
Fig. 1 also illustrates that both proteins are targeted to the 
mitochondria. UCP3S expression was on average 2-3 times 
greater than UCP3L expression. 
3.2. The effect of UCP3S on growth 
Both UCP3S and UCP3L inhibited growth of aerobically 
grown yeast. The average inhibition of growth by UCP3S 
(35_+ 7%), in comparison to control yeast, was lower than 
that obsdrved with UCP3L (52+ 3%) after growth for 14 h 
(n= 11). 
3.3. The effect of UCPs on whole yeast 02 consumption 
UCP3S and UCP3L increased the basal 02 consumption of
whole yeast by 26 and 48%, respectively (Fig. 2). Addition of 
the uncoupler ECCP increased O2 consumption of all yeast 
strains to a similar absolute rate. The observed increase in 
basal, but not maximally uncoupled respiration, is consistent 
with partial uncoupling activity induced by the presence of 
UCP3S and UCP3L. 
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Fig. 2. Whole yeast 02 consumption. Whole yeast 02 consumption 
was measured as described in Section 2. The maximal respiratory 
capacity was measured by adding 2 ~M FCCP. *P < 0.01versus the 
empty vector control. 
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Fig. 3. Mitochondrial membrane potential of yeast expressing 
UCP3L and UCP3S. Fluorescence histograms of DiOC6-treated 
cells expressing UCP3L, UCP3S and empty vector are shown. In 
each panel, the right histogram represents the cells with empty vec- 
tor. The left histogram shows the effect o  FCCP. The bold lines 
represent the cells expressing UCP3L and UCP3S. 
3.4. The effect of UCP3S on the mitochondrial membrane 
potential 
UCP3S decreased DiOC6 uptake as measured by flow cy- 
tometry to a similar degree as UCP3L (Fig. 3). This suggests 
that both proteins lower the mitochondrial membrane poten- 
tial. 
3.5. The effect oJ UCP3S on mitochondrial state 4 respiration 
The capacity of UCP3S to uncouple oxidative phosphoryl- 
ation was compared with that of UCP3L. The degree of un- 
coupling was determined by measuring the state 4 respiration 
of isolated mitochondria, i.e. respiration in the absence of 
added ADP and presence of oligomycin to inhibit ATP syn- 
thase. Under these conditions, mitochondrial O2 consumption 
is due to H + leak through the inner mitochondrial membrane. 
Typical respiratory tracings for the empty vector control, 
UCP3S and UCP3L are shown in Fig. 4A. State 4 respiration 
was increased to a similar degree in mitochondria containing 
UCP3S and UCP3L. As previously shown [17], GDP at a 
concentration of l mM had no effect on state 4 respiration 
with UCP3. UCP3S and UCP3L increased state 4 respiration 
by 33 and 35%, when expressed as percentage of FCCP-stimu- 
lated respiration (Fig. 4B). Although this increase in state 4 
respiration, expressed as percentage of the FCCP-stimulated 
respiration, is relatively small compared to the previously ob- 
served 102% increase with UCP1 [17], it is statistically signifi- 
cant compared to the empty vector control. 
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Fig. 4. Respiration in isolated mitochondria. Mitochondrial respira- 
tion was measured as described in Section 2. (A) Representative 
tracings for the empty vector control (Control), UCP3S and UCP3L 
are shown. The addition of 3 mM NADH, 2.5 gg/ml oligomycin, 
1 mM GDP and 2.5 ~JM FCCP as well as the 02 consumption i  
mnol O/min/mg mitochondrial protein are indicated. (B) State 4 res- 
piratory rates are expressed as percentage of the maximally un- 
coupled respiratory rate in the presence of FCCP. The data repre- 
sent the average of four experiments. *P< 0.05, **P< 0.005 versus 
the empty vector control. 
Mitochondria 
~32KD 
Fig. 5. Immunoblot analysis of the expression of the three UCP3L 
mutants in isolated mitochondria. 40 gg mitochondrial protein was 
used for analysis in each lane. 
among all mitochondrial  carriers of known sequence. The 
immunoblot  in Fig. 1 shows that mUCP3S is expressed at a 
similar level compared to UCP3S in isolated mitochondria.  
Since the greatest effects of UCP3S and UCP3L  were ob- 
served in whole yeast, we studied the ffect of mUCP3S on 
growth and whole yeast 02 consumption, mUCP3S inhibited 
yeast growth by 22.6 + 2.6%, thus the effect was intermediate 
between UCP3S (35.4 + 4.7% inhibition) and the empty vector 
control (n= 5). mUCP3S did not increase the whole yeast 
basal 02 consumption. The basal 02 consumption of yeast 
bearing mUCP3S was 41.9+5.6 nmol O/min/10 s cells 
(52.0% of the FCCP- induced rate). This rate was almost iden- 
tical to the basal rate of 41.4+6.1 nmol O/min/108 cells 
(51.3% of the FCCP-induced rate) with control yeast (n =4). 
This suggests that the mutant  protein has a greatly reduced 
activity. 
3.7. Study of three mUCP3 proteins (V9M, Vl021, R282C) 
The expression of the V9M and V102I mutant  proteins in 
isolated mitochondria was similar compared to wild-type 
UCP3L, that of R282C slightly increased (Fig. 5). The V9M 
and V102I mutants  had a similar inhibitory effect on growth 
and stimulatory effect on the whole yeast basal 02 consump- 
tion as wild-type UCP3L (Table 1). The R282C mutant  had 
an intermediate effect on both parameters. 
4. Discussion 
3.6. Characteristics of mUCP3, lackhTg the last three 
C-terminal amino acids 
mUCP3S, missing the three C-terminal amino acids tyro- 
sine, lysine and glycine, was studied as an additional negative 
control. These three residues are part of the carrier mot i f  
within the third intramatrix loop and are highly conserved 
This study investigated the uncoupling function f the short 
form of UCP3. This question is important  because individuals 
with a splice site mutat ion in the UCP3 gene, that results in 
the expression of UCP3S, have been found in different pop- 
ulations [22,23]. Three variants in the UCP3 sequence, result- 
ing in the alteration of residues that are highly conserved 
among the UCPs, were also studied. According to Chung et 
Table 1 
Growth inhibition and whole yeast basal 0 2 consumption i yeast expressing mUCP3L 
Growth inhibition compared to control 
(%) (n = 3) 
Whole yeast basal 02 consumption 
(% of FCCP-induced rate) (n = 4) 
Control 0 47.7 + 1.3 
UCP3L 52.4 _+ 5.7* 64.1 _+ 4.0** 
mUCP3L (V9M) 53.4 _+ 2.2*** 67.6 + 3.1 *** 
mUCP3L (V102I) 51.3 + 9.8* 61.7 _+ 2.0*** 
mUCP3L (R282C) 30.8 + 3.4* 53.8 _+ 1.8' 
Yeast growth was measured at 30°C in 3% lactate and no glucose containing SC-ura medium as described in Section 2. At time zero, yeast 
was diluted to an OD600 of 0.20 and galactose at a final concentration of 1% was added. After 14 h, the OD600 was measured and growth in- 
hibition was expressed as % inhibition compared to empty vector control yeast. Whole yeast 02 consumption was measured at 25°C in the 3% 
lactate containing medium. 2 gM FCCP was added to determine the maximum respiratory capacity. *P< 0.05, **P< 0.01, ***P< 0.005 versus 
the control. 
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al. [23], neither the splice site mutation or the three sequence 
variations resulted in a significant and consistent phenotype. 
This may be due to the fact that UCP3 does not function 
primarily as an UCP or that the short form and mutants of 
UCP3 are functional. 
This study demonstrates that the short form of UCP3 can 
be expressed in yeast mitochondria and is thus not subject o 
premature protein degradation or failure of protein import in 
yeast. Using available antibodies, we have not been able to 
detect UCP3L or UCP3S in human skeletal muscle mitochon- 
dria, which may be due to a low sensitivity of the antibodies 
used and/or low expression levels of the protein in humans. 
The long and short form of UCP3 have qualitatively similar 
biochemical ctivities when expressed in yeast. Both proteins 
reduced the yeast growth and mitochondrial membrane po- 
tential measured in whole yeast by uptake of the potential- 
sensitive dye DiOC6 and increased the whole yeast basal 02 
consumption. The magnitude of the effects was lower with 
UCP3S compared to UCP3L. Although these parameters 
are not specific for an uncoupling function, a previous tudy 
showed that UCP1 had similar effects on these parameters 
[17]. In addition, the oxoglutarate carrier, a closely related 
mitochondrial carrier without an uncoupling function, had 
no effect on yeast growth and basal 02 consumption and an 
effect on DiOC6 uptake that was intermediate b tween UCPs 
and empty vector control. Therefore, the measurements in 
whole yeast suggest uncoupling activity for UCP3L and 
UCP3S. 
Mitochondrial carrier proteins are composed of three se- 
quence repeats, each of which contains a characteristic mito- 
chondrial carrier sequence motif that is well-conserved among 
all mitochondrial carriers of known sequence [20,21]. Each of 
the three sequence repeats consists of two transmembrane c~-
helix domains and one extended matrix loop. Therefore, all 
mitochondrial carriers of known sequence possess ix trans- 
membrane domains. It may be argued that lack of the sixth 
transmembrane domain in UCP3S could prevent protein im- 
port into the inner mitochondrial membrane. However, 
UCP3S is truncated immediately after the third mitochondrial 
carrier motif. It was suggested that this carrier motif may play 
a role in protein importation into the inner mitochondrial 
membrane mediated by Tirol0 and Tirol2 [25]. Alternatively, 
the motif may facilitate correct protein folding or orientation. 
Therefore, as an additional negative control, we studied a 
mutant of UCP3S, lacking the last three C-terminal residues, 
tyrosine, lysine and glycine, of the carrier motif. Our results 
indicate a greatly reduced activity for mUCP3S compared to 
UCP3S. This may be due to impaired protein import of the 
mutant protein into the inner mitochondrial membrane. Alter- 
natively, the three residues may be essential for the folding, 
orientation or function of the protein. 
Our study of the three mUCP3L proteins indicates that the 
V9M and the VI02I mutants are functional and the R282C 
mutation is partially functional. These findings are not sur- 
prising, since the first two mutants result in the change of one 
neutral residue to another. In contrast, in the R282C mutant, 
a basic residue is converted into the reactive cysteine residue. 
Therefore, an impairment in protein function is not unex- 
pected. The residue is located within the last transmembrane 
domain that is missing in UCP3S. Thus, lack of arginine-282 
may contribute to the quantitatively decreased activity of 
UCP3S. Alternatively, the additional cysteine residue in the 
R282C mutant may have a deleterious effect on the function 
of the protein. 
The most specific parameter, when studying uncoupling ac- 
tivity, is measurement of state 4 respiration in isolated mito- 
chondria. When UCP1 is expressed in yeast, a strong increase 
in state 4, that is reversed upon addition of GDP, is observed 
[17,26]. In contrast, expression of the oxoglutarate carrier has 
no effect on state 4 respiration [17]. As previously observed 
for UCP3L [17], UCP3S increased state 4 respiration to a 
relatively small degree, when compared to UCP1. This dis- 
cordance between the strong effects of UCP3S and UCP3L 
in whole yeast and the small effect on state 4 respiration in 
isolated mitochondria requires further investigation. As dis- 
cussed in [17], one or more unidentified activators of UCP3S 
and UCP3L, that are present in whole yeast, may be missing 
when isolated mitochondria are studied. 
In summary, UCP3S could be expressed in yeast and was 
targeted to the mitochondria. UCP3S and UCP3L had qual- 
itatively similar effects in whole yeast and isolated mitochon- 
dria. Given the 2-3 times higher expression level of UCP3S 
compared to UCP3L, the activity of UCP3S is reduced com- 
pared to UCP3L. Thus, UCP3S appears to be a functional 
UCP, but with a modestly reduced activity compared to 
UCP3L. 
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